Relief Therapeutics Holding SA (ETR:RLF) | WebDisclosure

Basculer en Français

10964	Companies
240038	Keywords
168782	Articles
129138	Press releases

Headlines Articles Press releases Relief Therapeutics Holding SA

Home
Companies
Relief Therapeutics Holding SA

BRIEF

published on 09/01/2026 at 07:05, 10 days 4 hours ago

MindMaze Therapeutics présentera ses travaux lors de conférences clés.

Conférences D'investisseurs MindMaze Thérapeutique Neurothérapie Conférences Sectorielles Solutions En Neurotechnologie
BRIEF

published on 09/01/2026 at 07:05, 10 days 4 hours ago

MindMaze Therapeutics to Present at Key Conferences

Investor Conferences Industry Conferences MindMaze Therapeutics Neurotherapeutics Neurotechnology Solutions
PRESS RELEASE

published on 09/01/2026 at 07:00, 10 days 5 hours ago

MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences
MindMaze Therapeutics Holding SA to present at investor and industry conferences in Europe and the US, showcasing neurotechnology solutions and real-world evidence

Investor Conferences Real-world Evidence Industry Conferences MindMaze Therapeutics Neurotechnology Solutions
BRIEF

published on 08/27/2026 at 07:05, 15 days 4 hours ago

MindMaze Therapeutics présente ses résultats du premier semestre 2026

Résultats Financiers Mise À Jour De L'entreprise Expansion Américaine Stratégie De Remboursement Neurothérapie
BRIEF

published on 08/27/2026 at 07:05, 15 days 4 hours ago

MindMaze Therapeutics Presents 2026 Half-Year Results

Financial Results Corporate Update U.S. Expansion Reimbursement Strategy Neurotherapeutics
PRESS RELEASE

published on 08/27/2026 at 07:00, 15 days 5 hours ago

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update
MindMaze Therapeutics Holding SA announces 2026 Half-Year Results and Corporate Update, highlighting advancements, partnerships, and financial figures

Financial Report Corporate Update MindMaze Therapeutics Neurotherapeutics 2026 Half-Year Results
BRIEF

published on 08/12/2026 at 07:05, 30 days 4 hours ago

MindMaze Therapeutics nomme le professeur John W. Krakauer conseiller stratégique

Expansion Américaine MindMaze Thérapeutique Récupération Après Un AVC Neuroréadaptation John Krakauer
BRIEF

published on 08/12/2026 at 07:05, 30 days 4 hours ago

MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor

U.S. Expansion MindMaze Therapeutics Stroke Recovery Neurorehabilitation John Krakauer
PRESS RELEASE

published on 08/12/2026 at 07:00, 30 days 5 hours ago

MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
MindMaze Therapeutics appoints Prof. John W. Krakauer as strategic advisor to support growth in the United States. Dr. Krakauer is a leading figure in motor neuroscience, stroke recovery, and neurorehabilitation

Growth Strategic Advisor MindMaze Therapeutics Neurotherapeutics Prof. John W. Krakauer
BRIEF

published on 08/10/2026 at 07:05, 1 month 1 day ago

MindMaze Completes Simplification, Updates on Neuro.io Financing

Equity Financing MindMaze Neurotherapeutics Organizational Simplification Neuro.io

Accesswire

Published on 09/11/2026 at 04:00, 8 hours 4 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 39 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 18 hours 18 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 20 hours 44 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 21 hours 4 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 11:45, 18 minutes ago

Halfords Group PLC: Result of AGM
Published on 09/11/2026 at 11:43, 20 minutes ago

Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 28 minutes ago

EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 34 minutes ago

Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 1 hour 48 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050

Les Echos

Published on 09/11/2026 at 07:00, 5 hours 4 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 5 hours 4 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 5 hours 4 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 5 hours 4 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 16 hours 34 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE